About Dolutegravir Sodium,Rilpivirine Hydrochloride
Class: | Antiretroviral agent (Integrase Inhibitor and Non-Nucleoside Reverse Transcriptase Inhibitor combination)
Use: | Treatment of HIV-1 infection in adults who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen for at least 6 months without a history of treatment failure and no known resistance to the components of JULUCA.
Adult dose: | One tablet containing 50 mg of Dolutegravir Sodium and 25 mg of Rilpivirine Hydrochloride taken orally once daily
Drug Class
Antiretroviral agent (Integrase Inhibitor and Non-Nucleoside Reverse Transcriptase Inhibitor combination)
Uses & Indications
Treatment of HIV-1 infection in adults who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen for at least 6 months without a history of treatment failure and no known resistance to the components of JULUCA.
Storage Requirements
Store at room temperature (20°C to 25°C or 68°F to 77°F) in a tightly closed container, protected from moisture and light.
Manufacturer & Packaging
Manufacturer: VIIV HEALTHCARE Pty Ltd, AUSTRALIA
Package Size
30s
Price & Supplier
Price in UAE: AED 4243.50
Dosage Information
Adult Dose
One tablet containing 50 mg of Dolutegravir Sodium and 25 mg of Rilpivirine Hydrochloride taken orally once daily with food.
Pediatric Dose
Safety and efficacy have not been established in pediatric patients; not recommended for use in individuals under 18 years of age.
Side Effects
Common side effects include insomnia, headache, fatigue, nausea, diarrhea, and rash.
Contraindications & Precautions
Contraindicated in patients with a history of hypersensitivity to Dolutegravir, Rilpivirine, or any of the excipients. Also contraindicated with certain medications that induce CYP3A4 (e.g., rifampin, St. John's Wort).
Important Warnings
Risk of serious skin reactions and hypersensitivity reactions. Monitor for signs of depression and suicidal ideation. Not recommended for use in patients with active hepatitis B or C infection. Regular monitoring of liver function is advised.
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice.
Always consult with a licensed healthcare provider or pharmacist in the UAE before taking any medication.
The information presented here is specific to medicines available in UAE pharmacies and is regularly updated
to ensure accuracy for patients and healthcare professionals in the United Arab Emirates.